[CAS NO. 23325-78-2] Cephalexinmonohydrate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [23325-78-2]

Catalog

HY-B0200B

Brand

MCE

CAS

23325-78-2

DESCRIPTION [23325-78-2]

Overview

MDL	MFCD00167148
Molecular Weight	365.40
Molecular Formula	C16H19N3O5S
SMILES	O=C(C(N12)=C(C)CS[C@]2([H])[C@H](NC([C@H](N)C3=CC=CC=C3)=O)C1=O)O.O

For research use only. We do not sell to patients.

6 Publications Citing Use of MCE

Summary

Cephalexin (Cefalexin) monohydrate is a potent, orally active new semisynthetic cephalosporin antibiotic with a broad antibacterial spectrum. Cephalexin (Cefalexin) monohydrate has antibacterial activity against a wide variety of gram-positive and gram-negative bacteria. Cephalexin (Cefalexin) monohydrate targets penicillin-binding proteins (PBPs) to inhibit bacterial cell wall assembly. Cephalexin (Cefalexin) monohydrate is used for the research of pneumonia, strep throat, and bacterial endocarditis, et al ^[1] ^[2] .

In Vitro

Cephalexin (Cefalexin) monohydrate (10 μg/mL) disrupts polymer peptidoglycan (PG) biogenesis by inactivating enzymes called penicillin-binding proteins (PBPs) ^[1] .
Cephalexin (Cefalexin) monohydrate inhibits a broad spectrum of grampositive and gram-negative organisms with MIC values of 2, 2, 2, 2, 4, 4.4 and 5.7 μg/mL for Bacillus anthracis , Edwardsiella taFda , Vibrio cholera , Pasteurella multocida , Edwardsiella tarda , Alcaligenes sp and Proteus rettgeri , respectively ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cephalexin (Cefalexin) monohydrate (0-50 mg/kg; p.o.; for 3.5 hours) has antibacterial activity in male Swiss-Webster mice with infected bacterial ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss-Webster mice with infected bacterial ^[2]
Dosage:	0-50 mg/kg
Administration:	Oral administration; for 3.5 hours
Result:	Had antibacterial activity against Streptococcus pyogenes , Streptococcus pneumoniae , Staphylococcus aureus and several gram-negative species mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01002911	Population Health Research Institute	Arrythmias	December 2009	Phase 3
NCT04876131	Murdoch Childrens Research Institute\|Royal Children´s Hospital	Complicated Urinary Tract Infection\|Infection\|Pediatric Infectious Disease	May 30, 2022	Phase 4
NCT01073540	Bayer\|Corporación Bonima S.A. de C.V.	Anti-Infective Agents	September 2009	Phase 1
NCT01912651	University of Michigan	Facial Defect	July 2013	Phase 4
NCT01767532	GlaxoSmithKline	Infections, Respiratory Tract	January 30, 2011	Phase 1
NCT02911662	Saint Joseph Mercy Health System	Bacteriuria (Asymptomatic) in Pregnancy	September 2016	Not Applicable
NCT02014558	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Acute Myeloid Leukemia	October 9, 2013	Phase 1\|Phase 2
NCT01029782	Kelowna General Hospital\|Canadian Society of Hospital Pharmacists\|Capital Health, Canada\|Interior Health Authority, Canada	Cellulitis	May 2010	Phase 2
NCT02490670	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy	July 2015	Phase 1
NCT00729937	National Institute of Allergy and Infectious Diseases (NIAID)	Staphylococcal Infection	April 2009	Phase 2\|Phase 3
NCT04538053	Murdoch Childrens Research Institute	Bone Infection\|Septic Arthritis\|Bone and Joint Infection\|Osteomyelitis	June 1, 2021	Phase 4
NCT01073553	Bayer\|Corporación Bonima S.A. de C.V.	Anti-Infective Agents	October 2009	Phase 1
NCT01767584	GlaxoSmithKline	Infections, Respiratory Tract	April 6, 2009	Phase 1
NCT01595529	National Institute of Allergy and Infectious Diseases (NIAID)	Urinary Tract Infection	May 18, 2012	Phase 2
NCT00234949	Abbott	Mild to Moderate Uncomplicated Skin and Skin Structure Infections	March 2005	Phase 4
NCT03357419	Rambam Health Care Campus	Skin Lesion	March 2021	Not Applicable
NCT03802552	University of Colorado, Denver	Osteomyelitis\|Septic Arthritis\|Pyomyositis	May 1, 2019	Phase 1
NCT02145338	Newcastle-upon-Tyne Hospitals NHS Trust\|NHS Health Technology Assessment Programme\|Newcastle University\|Glasgow Caledonian University\|University of Aberdeen\|Cambridge University Hospitals NHS Foundation Trust\|North Bristol NHS Trust\|University of Southampton	Urinary Tract Infections, Recurrent	September 2013	Phase 4
NCT04580472	Carilion Clinic	Surgical Site Infection	October 1, 2020	Phase 4
NCT01194115	University of Cincinnati	Surgical Site Infection in Obese Women Undergoing C-section	September 2010	Not Applicable
NCT03736187	Ain Shams University	Surgical Site Infection	April 2019	Not Applicable
NCT04916951	University of Colorado, Denver	Neonatal Infection	July 14, 2021	Phase 1
NCT02123459	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy Volunteers	May 2014	Phase 1
NCT02100826	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy Volunteers	April 2014	Phase 1
NCT04834310	University of California, Los Angeles	Surgical Site Infection\|Capsular Contracture Associated With Breast Implant\|Antibiotic Resistant Infection\|Antibiotic Side Effect	April 1, 2021	Phase 4
NCT01767571	GlaxoSmithKline	Infections, Respiratory Tract	January 30, 2011	Phase 1
NCT00003824	Southwest Oncology Group\|National Cancer Institute (NCI)	Bladder Cancer	April 1999	Phase 3
NCT00676130	Brigham and Women´s Hospital	Cellulitis	May 2007	Not Applicable
NCT04553419	University of British Columbia\|The Hospital for Sick Children	Cystic Fibrosis	July 27, 2020	Phase 3
NCT05020574	University of California, San Francisco\|The Plastic Surgery Foundation	Breast Cancer\|Breast Cancer Female\|Genetic Predisposition to Disease	September 28, 2021	Phase 2
NCT04194216	Stanford University\|Washington University School of Medicine\|Vanderbilt University School of Medicine\|University of Washington\|Duke University\|Harvard University\|University of Kansas Medical Center\|University of Cincinnati\|Loma Linda University	Nasal Obstruction\|Nasal Surgical Procedures	May 20, 2020	Phase 3
NCT02123446	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy Volunteers	April 2014	Phase 1
NCT05274672	Baylor Research Institute\|Albert Einstein Healthcare Network	Benign Prostatic Hyperplasia\|Urinary Tract Infections	March 1, 2022	Phase 4
NCT02569866	Federal University of São Paulo\|Universidade do Vale do Sapucai	Surgical Site Infection	November 2014	Phase 2
NCT04577846	Aga Khan University\|Liaquat National Hospital & Medical College\|Dow University of Health Sciences	Surgical Site Infection	November 1, 2020	Phase 3
NCT01400867	Forest Laboratories\|AstraZeneca	Infections, Pediatrics	December 2011	Phase 2\|Phase 3
NCT01507974	HaEmek Medical Center, Israel	Pregnancy Complications	January 16, 2012	Not Applicable
NCT00187759	University of California, San Francisco	Soft Tissue Infections	November 2004	Not Applicable
NCT03148444	Kaplan Medical Center	Infection, Bacterial\|Pacemaker Complication	June 1, 2017	Phase 4
NCT00352612	Aaron Chen\|Thrasher Research Fund\|Johns Hopkins University	Staphylococcal Infection\|Abscess\|Staphylococcal Skin Infection\|Folliculitis	September 2006	Phase 4
NCT01631617	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\|National Institutes of Health Clinical Center (CC)	Eczema\|Dermatitis\|Skin Diseases, Genetic\|Dermatitis, Atopic\|Skin Diseases	September 18, 2012	Phase 2
NCT04297592	University of Iowa	Infections Joint Prosthetic\|Overweight or Obesity\|MSSA Colonization\|MRSA\|Chronic Kidney Diseases\|Diabetes\|Autoimmune Diseases\|Inflammatory Disease\|Tobacco Use	June 11, 2020	Phase 4
NCT04471246	Ottawa Hospital Research Institute\|The Ottawa Hospital Academic Medical Association\|Canadian Association of Emergency Physicians	Cellulitis	August 16, 2021	Phase 4
NCT02123472	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy Volunteers	May 2014	Phase 1
NCT03187106	The University of Texas Medical Branch, Galveston	Surgical Site Infection	August 1, 2017	Phase 1
NCT01155154	State University of New York - Downstate Medical Center\|Staten Island University Hospital\|Kings County Hospital Center	Simple Hand Lacerations	February 2010	Not Applicable
NCT01105208	Bayer\|Corporación Bonima S.A. de C.V.	Anti-Infective Agents	March 2010	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 6.67 mg/mL ( 18.25 mM ; Need ultrasonic)

H ₂ O : 2 mg/mL ( 5.47 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7367 mL	13.6836 mL	27.3673 mL
5 mM	0.5473 mL	2.7367 mL	5.4735 mL
10 mM	0.2737 mL	1.3684 mL	2.7367 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 8.33 mg/mL (22.80 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 0.67 mg/mL (1.83 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 0.67 mg/mL (1.83 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 0.67 mg/mL (1.83 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-, hydrate (1:1), (6R,7R)-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, monohydrate, D-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-8-oxo-, monohydrate, [6R-[6α,7β(R*)]]-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-aminophenylacetyl]amino]-3-methyl-8-oxo-, monohydrate, (6R,7R)-

Cephalexin monohydrate

Purilex

Lexine

Rivalexin

Pharmexin

Cephalexin Asia